Which companies are Senores Pharmaceuticals's closest peers?

The cockpit's peer set: Beijing Science Sun Pharmaceutical (300485.SZ), Bicara Therapeutics (BCAX), Nanjing Hicin Pharmaceutical (300584.SZ), Ovid Therapeutics (OVID), Chimin Health Management (603222.SS), Orchid Pharma (ORCHPHARMA.NS), Entera Bio (ENTX), Jiangsu Lianhuan Pharmaceutical (600513.SS).

Is Senores Pharmaceuticals expensive compared with its peers?

On forward p/e it trades at 34.2× against a peer median of 10.9×, 2nd most expensive of 8 in its peer set.

How has Senores Pharmaceuticals stock performed?

Over six months to 6 Nov 2026 the shares returned +24.6% against -18.2% for the median peer; over one year +49.7%.

← CockpitCompetitor Analysis › SENORES.NS Senores Pharmaceuticals Ltd.Open in the cockpit ↗

Senores Pharmaceuticals Ltd.SENORES.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Momentum neutral 53

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$566M

US dollars, full cap

Free float

46%

of shares outstanding

$/day

$4.77M

20-day average traded

Fwd P/E

34.2×

forward earnings

ROIC−WACC

-0.1 pp

WACC 9.7%

Hurdle

n/a

no reverse DCF

Next earnings

83 days

28 Jan 2027

Close · INR₹1,161

1D-2.3%

1W+2.4%

1M-16.4%

3M-12.6%

6M+24.6%

YTD+41.2%

1Y+49.7%

ATR %5.7%

Beta0.83

52w lowhigh27.4% off high

What Senores Pharmaceuticals does

Employees: 368

Senores Pharmaceuticals at a glance

Size Senores Pharmaceuticals (SENORES.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $566M, the 795th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,161 on 6 Nov 2026.

Performance Over six months the shares gained 24.6%, against -18.2% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 39.7% over the last twelve months (peer median +4.5%); the operating margin is 24.3% (peer median 5.5%).

Valuation It trades at 34.2× forward earnings against a peer median of 10.9× (2nd most expensive of 8).

Capital Return on invested capital runs 0.1 points below its cost of capital (9.7% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Senores Pharmaceuticals against the median of its 20 peers (local-currency closes).

Senores Pharmaceuticals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₹7.22B	₹6.33B	₹3.97B	₹2.14B	₹353M
Revenue growth	—	+59%	+86%	+506%	—
Gross profit	₹2.96B	₹2.07B	₹1.21B	₹541M	₹160M
EBITDA	₹2.13B	₹1.68B	₹888M	₹411M	₹127M
Net income	₹1.33B	₹1.15B	₹586M	₹315M	₹84.3M
Free cash flow	n/a	-₹2.13B	-₹2.17B	-₹856M	-₹502M
Capital expenditure	n/a	₹2.65B	₹1.58B	₹518M	₹473M
Total debt	₹4.17B	₹3.42B	₹3.15B	₹2.58B	₹626M

Quarterly statements and history in the cockpit →

Senores Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Senores Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Senores Pharmaceuticals is the large dot.

Senores Pharmaceuticals competitors and peer comparison

How Senores Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Senores Pharmaceuticals against its 20 peers (data as of 6 Nov 2026)
Measure	SENORES.NS	Peer median	Rank in peer set
1-month return	-16.4%	-8.8%	6th lowest of 21
6-month return	+24.6%	-18.2%	3rd highest of 21
Distance from 52-week high	-27.4%	-34.2%	7th highest of 21
Revenue growth (TTM)	+39.7%	+4.5%	highest of 20
Operating margin	24.3%	5.5%	4th highest of 19
Forward P/E	34.2×	10.9×	2nd most expensive of 8
ROIC minus cost of capital	-0.1 pp	-2.7 pp	8th highest of 18
EV / EBITDA	26.7×	15.2×	most expensive of 4
Net debt / EBITDA	1.5×	2.5×	3rd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Senores Pharmaceuticals SENORES.NS	India	$566M	+25%	+40%	24%	34.2×	n/a	n/a
Beijing Science Sun Pharmaceutical 300485.SZ	China	$566M	-28%	-11%	-8%	n/a	n/a	n/a
Bicara Therapeutics BCAX	United States	$572M	-62%	n/a	n/a	n/a	n/a	n/a
Nanjing Hicin Pharmaceutical 300584.SZ	China	$573M	-25%	+32%	17%	n/a	5.5%	-1.1%
Ovid Therapeutics OVID	United States	$557M	+2%	-76%	-3,687%	n/a	n/a	n/a
Chimin Health Management 603222.SS	China	$553M	-28%	+1%	-28%	n/a	n/a	n/a
Orchid Pharma ORCHPHARMA.NS	India	$551M	+27%	+11%	0%	75.5×	n/a	n/a
Entera Bio ENTX	United States	$546M	+142%	-100%	n/a	n/a	n/a	n/a
Jiangsu Lianhuan Pharmaceutical 600513.SS	China	$546M	-44%	+14%	0%	n/a	n/a	n/a
Jinling Pharmaceutical 000919.SZ	China	$586M	-14%	-8%	1%	n/a	5.0%	+5.0%
Jinhe Biotechnology 002688.SZ	China	$587M	-22%	+9%	5%	9.5×	14.8%	+9.7%
Shanghai Xiao Fang Pharmaceutical 603207.SS	China	$544M	-14%	+10%	39%	n/a	-3.9%	+7.6%
Abbisko Cayman 2256.HK	Hong Kong	$589M	-48%	-83%	-520%	n/a	n/a	n/a
Zeria Pharmaceutical 4559.T	Japan	$540M	-6%	+12%	15%	9.3×	-12.5%	+11.1%
Supriya Lifescience SUPRIYA.NS	India	$593M	-1%	+28%	30%	23.6×	27.9%	+15.8%
Xizang Weixinkang Pharmaceutical 603676.SS	China	$538M	-22%	-8%	16%	n/a	-5.2%	+9.6%
TTY Biopharm 4105.TWO	Taiwan	$596M	+7%	+5%	33%	10.9×	-11.1%	+8.8%
Tianjin Lisheng Pharmaceutical 002393.SZ	China	$598M	-23%	-3%	7%	9.7×	-3.2%	+4.1%
ChengDa PharmaCeuticals 301201.SZ	China	$535M	-43%	+27%	-9%	n/a	n/a	n/a
Henan Taloph Pharmaceutical Stock 600222.SS	China	$533M	-5%	-5%	7%	n/a	17.7%	+4.4%
Boryung 003850.KS	South Korea	$531M	-14%	+6%	6%	11.1×	-8.9%	+12.6%

Questions

Which companies are Senores Pharmaceuticals's closest peers?: The cockpit's peer set: Beijing Science Sun Pharmaceutical (300485.SZ), Bicara Therapeutics (BCAX), Nanjing Hicin Pharmaceutical (300584.SZ), Ovid Therapeutics (OVID), Chimin Health Management (603222.SS), Orchid Pharma (ORCHPHARMA.NS), Entera Bio (ENTX), Jiangsu Lianhuan Pharmaceutical (600513.SS).
Is Senores Pharmaceuticals expensive compared with its peers?: On forward p/e it trades at 34.2× against a peer median of 10.9×, 2nd most expensive of 8 in its peer set.
How has Senores Pharmaceuticals stock performed?: Over six months to 6 Nov 2026 the shares returned +24.6% against -18.2% for the median peer; over one year +49.7%.